Ali BOLAT, Savaş SARIKAYA, Yunus Keser YILMAZ, Hasan EKİM

PERKÜTANÖZ KORONER ANJİOGRAFİ SONRASI GELİŞEN HEMATOM VE EKİMOTİK CİLT LEZYONLU BİR VAKA

Vasküler komlikasyonlar koroner anjiyografi ve perkütanöz koroner girişim sonrası geli- şebilir. Femoral arter ponksiyonu vasküler erişimde en yaygın olarak kullanılan metot- lardan biridir. Kompleks kardiyovasküler girişimsel işlemler sonrası (stent implantasyonu, aortik valvüloplasti, ve intraaortik balon pompası veya kardiyopulmoner baypas destek kullanımı dahil ) vasküler giriş yeri komplikasyonu gelişme olasılığı artmıştır. Biz burada perkütan femoral arter girişimi yapılan hastada gelişen femoral hematom ve yaygın cilt ekimozlu bir olguyu sunuyoruz.

A Case with Echymotic Skin Lesion and Hematome developing after Percutaneous Coronary Angiography

Vascular complications may develop after coronary angiography and percutaneous coronary intervention. Femoral arterial puncture is one of the most common method of vascular access. Complex cardiovascular interventional procedures (including coronary stent implantation, aortic valvuloplasty, and the use of an intraaortic balloon pump or cardiopulmonary bypass support) are associated with increased vascular access site complications. We presented a patient who had femoral hematoma and extend skin ecchymosis developed after coronary angiography.

PDF

___

1. Pracyk J.B., Wall T.C., Longabaugh J.P., Tice F.D., Hochrein J., Green C et al. A randomized trial of vascular hemostasis techniques to reduce femoral vascular complications after coronary intervention. Am J Cardiol 1998;81(8):970-6.
2. Davis C., VanRiper S., Longstreet J., Moscucci M.: Vascular complications of coronary interventions. Heart Lung 1997: 26(2) 113-7.
3. Rudisill P, Williams L, Craig S, Schopp P. Study of mechanical versus manual/mechanical compression following various interventional cardiology procedures. J Cardiovasc Nurs 1997;11:15-21.
4. Waksman R., King S.B. 3rd, Douglas J.S., Shen Y., Ewing H., Mueller L., et al. Predictors of groin complications after balloon and new-device coronary intervention. Am J Cardiol 1995;75(14):886-9.
5. Sabo J., Chlan L.L., Savik K.: Relationships among patient characteristics,comorbidities, and vascular complications post-percutaneous coronary intervention. Heart & Lung 2008: 37(3);190-5.
6. Katırcıbaşı MT, Çamsarı A, Döven O, Pekdemir H, Akkuş N, Çiçek D et al. Perkütan Koroner Girişimler Sonrası Femoral Vasküler Komplikasyonlar. Anadolu Kardiyoloji Dergisi 2004;4:39-44.
7. Tavris D.R., Gallauresi B.A., Lin B., Rich S.E., Shaw R.E., Weintraub W.S., et al. Risk of local adverse events following cardiac catheterization by hemostasis device use and gender. J Invasive Cardiol 2004;16(9):45964.
8. avris D.R., Dey S., Albrecht-Gallauresi B., Brindis R.G., Shaw R., Weintraub W.et al. Risk of local adverse events following cardiac catheterization by hemostasis device use: phase II. J Invasive Cardiol 2005;17(12):644 50.
14. Applegate R J, Sacrinty M T, Kutcher M A, Kahl FR, Gandhi SK, Santo Renato M.S, at al.Trends in Vascular Complications After Diagnostic Cardiac Catheterization and Percutaneous Coronary Intervention Via the Femoral Artery 2008;1(3) 17-26.
9. Nikolsky E., Mehran R., Dangas G., Fahy M., Na Y., Pocock S.J., et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007;28(16):1936 45.
10. Lincoff A.M., Kleiman N.S., Kereiakes D.J., Feit F., Bittl J.A., Jackman J.D et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/ IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004;292(6):690-3.
11. Turi ZG. Optimizing vascular access: routine femoral angiography keeps the vascular complication away. Catheter Cardiovasc Interv 2005;65(2):203 4.
12. Nikolsky E., Mehran R., Halkin A., Aymong E.D., Mintz G.S., Lasic Z., et al. Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: a meta-analysis. J Am Coll Cardiol 2004;44(6):1200 9.
13. The EPILOG Investigators. Effect of the platelet glycoprotein IIb/IIIa receptor inhibitor abciximab with lower heparin dosages on ischemic complications of percutaneous coronary revascularization. N Engl J Med 1997;336(24):1689 96.